Nautilus Biotechnology (NAUT) Competitors

$2.54 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.52 -0.02 (-0.91%)

As of 05/22/2026 07:55 PM Eastern

NAUT vs. ALNT, EYPT, TRNS, FEIM, and CTKB

Should you buy Nautilus Biotechnology stock or one of its competitors? MarketBeat compares Nautilus Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nautilus Biotechnology include Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), and Cytek Biosciences (CTKB). These companies are all part of the "measuring and control equipment" industry.

How does Nautilus Biotechnology compare to Allient?

Nautilus Biotechnology (NASDAQ:NAUT) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Allient has a net margin of 4.25% compared to Nautilus Biotechnology's net margin of 0.00%. Allient's return on equity of 12.47% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Allient	4.25%	12.47%	6.37%

Nautilus Biotechnology has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Allient has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

In the previous week, Allient had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 1 mentions for Allient and 0 mentions for Nautilus Biotechnology. Allient's average media sentiment score of 0.40 beat Nautilus Biotechnology's score of 0.00 indicating that Allient is being referred to more favorably in the news media.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Allient	Neutral

Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 57.48%. Allient has a consensus price target of $72.25, indicating a potential upside of 14.01%. Given Nautilus Biotechnology's higher probable upside, research analysts clearly believe Nautilus Biotechnology is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Allient has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Allient	$554.48M	1.94	$22.03M	$1.43	44.31

Summary

Allient beats Nautilus Biotechnology on 13 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Eyepoint Pharmaceuticals presently has a consensus target price of $31.80, suggesting a potential upside of 145.94%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 57.48%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Nautilus Biotechnology's return on equity of -35.04% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Nautilus Biotechnology has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	34.56	-$231.96M	-$3.50	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 0 mentions for Nautilus Biotechnology. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 equaled Nautilus Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Nautilus Biotechnology	Neutral

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eyepoint Pharmaceuticals beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Transcat?

Nautilus Biotechnology (NASDAQ:NAUT) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Nautilus Biotechnology has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Transcat has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Transcat has a net margin of 2.47% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 6.15% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Transcat	2.47%	6.15%	4.15%

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 57.48%. Transcat has a consensus target price of $105.33, indicating a potential upside of 44.25%. Given Nautilus Biotechnology's higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Transcat had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 1 mentions for Transcat and 0 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.00 equaled Transcat'saverage media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Transcat	Neutral

Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Transcat	$278.42M	2.45	$14.52M	$0.85	85.91

Summary

Transcat beats Nautilus Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Frequency Electronics?

Nautilus Biotechnology (NASDAQ:NAUT) and Frequency Electronics (NASDAQ:FEIM) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 58.6% of Frequency Electronics shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 28.0% of Frequency Electronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Frequency Electronics has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Frequency Electronics	$69.81M	9.59	$23.69M	$0.75	90.68

Nautilus Biotechnology has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Frequency Electronics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Frequency Electronics has a net margin of 10.78% compared to Nautilus Biotechnology's net margin of 0.00%. Frequency Electronics' return on equity of 12.69% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Frequency Electronics	10.78%	12.69%	7.84%

In the previous week, Frequency Electronics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Frequency Electronics and 0 mentions for Nautilus Biotechnology. Frequency Electronics' average media sentiment score of 0.10 beat Nautilus Biotechnology's score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Frequency Electronics	Neutral

Nautilus Biotechnology currently has a consensus target price of $4.00, suggesting a potential upside of 57.48%. Frequency Electronics has a consensus target price of $43.67, suggesting a potential downside of 35.79%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Frequency Electronics beats Nautilus Biotechnology on 12 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Cytek Biosciences' return on equity of -10.07% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nautilus Biotechnology has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.57	-$66.54M	-$0.57	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Cytek Biosciences has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 41.83%. Nautilus Biotechnology has a consensus price target of $4.00, suggesting a potential upside of 57.48%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cytek Biosciences had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 1 mentions for Cytek Biosciences and 0 mentions for Nautilus Biotechnology. Cytek Biosciences' average media sentiment score of 0.00 equaled Nautilus Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Cytek Biosciences	Neutral
Nautilus Biotechnology	Neutral

Summary

Cytek Biosciences beats Nautilus Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$322.78M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-5.52	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	2.23	7.09	10.37	7.14
Net Income	-$59M	$24.45M	$3.57B	$335.98M
7 Day Performance	6.72%	6.38%	6.40%	4.15%
1 Month Performance	-3.05%	2.43%	3.52%	2.54%
1 Year Performance	246.95%	62.98%	34.02%	35.05%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.8405 of 5 stars	$2.54 flat	$4.00 +57.5%	+246.9%	$322.78M	N/A	N/A	130
ALNT Allient	3.8988 of 5 stars	$61.00 +0.1%	$72.25 +18.4%	+112.1%	$1.04B	$554.48M	42.66	2,478
EYPT Eyepoint Pharmaceuticals	2.3878 of 5 stars	$11.82 +1.0%	$31.80 +169.0%	+127.6%	$980.94M	$31.37M	N/A	120
TRNS Transcat	2.4817 of 5 stars	$69.64 -10.4%	$105.33 +51.3%	-20.0%	$725.20M	$278.42M	81.93	1,245	Upcoming Earnings
FEIM Frequency Electronics	1.5421 of 5 stars	$57.95 +0.3%	$43.67 -24.6%	+256.6%	$568.57M	$69.81M	77.27	200	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. ALNT, EYPT, TRNS, FEIM, and CTKB

How does Nautilus Biotechnology compare to Allient?

Summary

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Summary

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. ALNT, EYPT, TRNS, FEIM, and CTKB

How does Nautilus Biotechnology compare to Allient?

Do institutionals and insiders hold more shares of NAUT or ALNT?

Is NAUT or ALNT more profitable?

Which has more volatility & risk, NAUT or ALNT?

Does the media prefer NAUT or ALNT?

Do analysts rate NAUT or ALNT?

Which has better earnings and valuation, NAUT or ALNT?

Summary

How does Nautilus Biotechnology compare to Eyepoint Pharmaceuticals?

Do analysts prefer EYPT or NAUT?

Which has more risk and volatility, EYPT or NAUT?

Is EYPT or NAUT more profitable?

Which has stronger valuation & earnings, EYPT or NAUT?

Does the media favor EYPT or NAUT?

Do insiders & institutionals have more ownership in EYPT or NAUT?

Summary

How does Nautilus Biotechnology compare to Transcat?

Which has more risk & volatility, NAUT or TRNS?

Do insiders & institutionals believe in NAUT or TRNS?

Is NAUT or TRNS more profitable?

Do analysts recommend NAUT or TRNS?

Does the media refer more to NAUT or TRNS?

Which has stronger earnings & valuation, NAUT or TRNS?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Do institutionals and insiders have more ownership in NAUT or FEIM?

Which has stronger earnings & valuation, NAUT or FEIM?

Which has more risk & volatility, NAUT or FEIM?

Is NAUT or FEIM more profitable?

Does the media refer more to NAUT or FEIM?

Do analysts prefer NAUT or FEIM?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Is CTKB or NAUT more profitable?

Do institutionals & insiders hold more shares of CTKB or NAUT?

Which has higher valuation and earnings, CTKB or NAUT?

Which has more volatility and risk, CTKB or NAUT?

Do analysts recommend CTKB or NAUT?

Does the media prefer CTKB or NAUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools